TY - JOUR
T1 - Review of experimental compounds demonstrating anti-Toxoplasma activity
AU - McFarland, Madalyn M.
AU - Zach, Sydney J.
AU - Wang, Xiaofang
AU - Potluri, Lakshmi Prasad
AU - Neville, Andrew J.
AU - Vennerstrom, Jonathan L.
AU - Davis, Paul H.
N1 - Funding Information:
This work was funded by HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID AI116723) (J.L.V.) and HHS| NIH | National Institute of General Medical Sciences (NIGMS GM103427) (P.H.D.). Additionally, the following support is acknowledged: the Nebraska Research Initiative (P.H.D.) and the University of Nebraska at Omaha FUSE and GRACA (M.M.M.).
Publisher Copyright:
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
PY - 2016/12
Y1 - 2016/12
N2 - Toxoplasma gondii is a ubiquitous apicomplexan parasite capable of infecting humans and other animals. Current treatment options for T. gondii infection are limited and most have drawbacks, including high toxicity and low tolerability. Additionally, no FDA-approved treatments are available for pregnant women, a high-risk population due to transplacental infection. Therefore, the development of novel treatment options is needed. To aid this effort, this review highlights experimental compounds that, at a minimum, demonstrate inhibition of in vitro growth of T. gondii. When available, host cell toxicity and in vivo data are also discussed. The purpose of this review is to facilitate additional development of anti-Toxoplasma compounds and potentially to extend our knowledge of the parasite.
AB - Toxoplasma gondii is a ubiquitous apicomplexan parasite capable of infecting humans and other animals. Current treatment options for T. gondii infection are limited and most have drawbacks, including high toxicity and low tolerability. Additionally, no FDA-approved treatments are available for pregnant women, a high-risk population due to transplacental infection. Therefore, the development of novel treatment options is needed. To aid this effort, this review highlights experimental compounds that, at a minimum, demonstrate inhibition of in vitro growth of T. gondii. When available, host cell toxicity and in vivo data are also discussed. The purpose of this review is to facilitate additional development of anti-Toxoplasma compounds and potentially to extend our knowledge of the parasite.
UR - http://www.scopus.com/inward/record.url?scp=84996560082&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84996560082&partnerID=8YFLogxK
U2 - 10.1128/AAC.01176-16
DO - 10.1128/AAC.01176-16
M3 - Review article
C2 - 27600037
AN - SCOPUS:84996560082
VL - 60
SP - 7017
EP - 7034
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
SN - 0066-4804
IS - 12
ER -